Phi29 DNA-Packaging Motor for Nanomedicine

创新的生物机器，如纳米马达和膜通道，激发了 仿生设备，可以为疾病诊断提供细胞过程的精密控制， 治疗phi 29是迄今为止最强大的生物发动机。电机是可切换的，强调其 与所有其他体外病毒包装马达相比，DNA插入效率最高， 作为纳米技术应用中的机械组件的可行选择。的长期目标 拟议的Nanostim药物递送中心是创造生物相容的膜和阵列， 嵌入式phi 29 DMA封装电机，用于医学应用。这将通过集中精力 在三个关键领域的研究：逆向工程的phi 29电机;纳入积极纳米到 脂质双层;以及开发能够实现药物递送和诊断的活性纳米阵列。 该中心的短期目标是创建嵌入phi 29 DNA的脂质体和阵列结构， 用于被动和主动运输DNA和药物的包装马达。该中心将开发混合动力 结合了生物纳米颗粒和合成递送系统的最佳特征的联合收割机系统， 目前已获得临床认可。最初的努力将提供该结构的工程规格 and working加工mechanism机制of the phi 29 nanomotor纳米motor马达that will enable使us to produce生产engineered工程，hybrid杂交，synthetic合成 和功能性纳米马达。在脂质体中掺入活性phi 29纳米马达将是一个主要的推动力， 将使纳米控制的治疗方法，已经获得了临床接受 但是仍然仅仅提供用于治疗复杂病症（例如癌症和感染性疾病）的钝器械 疾病额外的团队努力将利用我们对重组膜适应的理解， 马达，以创建用于诊断应用的原型纳米机械设备， 治疗学和各种纳米机器在医学中的应用。这些应用程序和 物理作用、能量转导和跨膜转运的工程原理 我们的跨学科团队将阐明膜适应马达的能力， 物理学家、化学家、工程师、数学家、医生和分子生物学家。

Innovative biological machines, such as nanomotors and membrane channels, inspire the development of biomimetic devices that can provide the exquisite control of cellular processes for disease diagnostics and treatment. The phi29 is the strongest biomotor constructed to date. The motor is switchable, underscoring its highest efficiency in DNA insertion compared to all other in vitro viral packaging motors, making the motor a viable option as a mechanical component in nanotechnology applications. The long-term goal of the proposed Nanomotor Drug Delivery Center is to create biologically compatible membranes and arrays with embedded phi29 DMA-packaging motors for applications in medicine. This will be accomplished by focusing on three key areas of study: reverse engineering the phi29 motor; incorporating the active nanomotor into lipid bilayers; and developing active nanomotor arrays that enable drug delivery and diagnostics. The short-term goal of this center is to create liposomes and array structures with embedded phi29 DNA- packaging motors for both passive and active transport of DNA and drugs. The Center will develop hybrid systems that combine the best features of the biological nanomotor and synthetic delivery systems that have already achieved clinical acceptance. Initial efforts will provide engineering specifications for the structure and working mechanism of the phi29 nanomotorthat will enable us to produce engineered, hybrid, synthetic and functional nanomotors. Incorporation of active phi29 nanomotors in liposomes will be a major thrust that will enable nanoscale control for therapeutic approaches that have already gained acceptance in the clinic but still provide only blunt instruments for therapy of complex conditions such as cancer and infectious diseases. Additional team efforts will exploit our understanding of the reengineered membrane-addapted motor to create prototype nanomechanical devices for diagnostic applications, targeted delivery of therapeutics and for various nanomachines with application in medicine. These applications and the engineering principles underlying the physical action, energy transduction and transmembrane transport capabilities of the membrane adapted motors will be elucidated by our interdisciplinary team including physicists, chemists, engineers, mathematicians, physicians, and molecular biologists.